Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians' Education Resource®, LLC designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians' Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669.
Acknowledgment of Commercial Support
This activity is supported by an educational grant from Shionogi Inc.
Best Practice™: Optimizing Outcomes in Patients Awaiting Liver Transplantation: Addressing Thrombocytopenia in Patients with CLD Scheduled for Procedure
Optimizing Outcomes in Patients Awaiting Liver Transplantation: Addressing Thrombocytopenia in Patients with CLD Scheduled for Procedure
In order to request this CME/CE activity for your center, please contact Samantha Zelasko at SZelasko@gotoper.com or call (609) 325-4668
Thrombocytopenia is one of the most common complications in patients with chronic liver disease, which poses many challenges for effective treatment. Recent advances in the understanding of pathophysiological mechanisms of thrombocytopenia in CLD has resulted in development of novel treatment options. One of the major contributors to the development of thrombocytopenia in cirrhosis appears to be decreased hepatic production. Since the occurrence of thrombocytopenia in patients with CLD can elevate the risk of bleeding associated with invasive or surgical procedures and delay or prevent crucial interventions, it is imperative that clinicians are updated on the evolving treatment landscape to enable informed treatment decisions.
Benefits of Attending
- Gain expert insights into the unique pathophysiology of thrombocytopenia in chronic liver disease
- Recognize the clinical implications and bleeding risks associated with thrombocytopenia in patients with CLD who are scheduled to undergo a procedure
- Evaluate the clinical efficacy and safety of current therapeutic agents for the treatment of thrombocytopenia in patients with ESLD
- Develop management strategies to optimize care of thrombocytopenia in patients with CLD who are scheduled to undergo a procedure
This educational program is primarily directed toward hepatologists and gastroenterologists who treat and/or operate on patients with CLD with thrombocytopenia who are scheduled to undergo a procedure. Additionally, fellows, nurses, nurse practitioners, physician assistants, and other healthcare professions (HCPs) involved in the treatment of CLD will also be invited to participate in the activity.
Upon completion of this activity, participants will be able to:
- Describe the development of thrombocytopenia in CLD leading to increased risk of bleeding
- Evaluate the potential impact of trial data on clinical practice regarding new therapeutic agents for thrombocytopenia in patients who are scheduled to undergo a procedure
- Identify evaluation and referral strategies to optimize care of thrombocytopenia in patients with CLD who are scheduled to undergo a procedure
Chief, Division of Gastroenterology, Department of Medicine
Member, Duke Clinical Research Institute
Duke University Medical Center